Despite contemporary advances in transcatheter aortic valve replacement (TAVR), procedural strokes remain a weakness of the procedure.1 Cerebral embolic protection devices (EPDs) emerged as a potential method to decrease the risk of post-TAVR strokes. However, data supporting the use of EPDs are conflicting. In the Cerebral Protection in TAVR trial, EPDs did not reduce the rate of post-TAVR stroke, although embolic debris was captured in 99% of filters.2 However, observational data and pooled analyses have suggested a potential benefit of EPDs.3,4 This study sought to evaluate the early post–US Food and Drug Administration approval experience with the Sentinel device (Boston Scientific), the only EPD available in the United States.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Alkhouli M, Alqahtani F, Harris AH, Hohmann SF, Rihal CS. Early Experience With Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement in the United States. JAMA Intern Med. 2020;180(5):783–784. doi:10.1001/jamainternmed.2019.6767
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: